Targeting purine catabolism and signaling in T cell autoimmunity
Active Grant Awarded
- Award ID
- R37AI114581
- Recipient
-
Research Institute At Nationwide Children's Hospital UEI EYMJXLN2MFB4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $490,216
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 5% complete
- Place of performance
- Columbus, OH 43205, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded Research Institute At Nationwide Children's Hospital $490,216 in obligated funding on August 31, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant funds research on purine metabolism in T-cell autoimmunity. The proposal aims to determine how the purine nucleosides adenosine and inosine regulate T-cell inflammation and to explore the therapeutic potential of targeting purine metabolism and signaling in animal models of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis. The hypothesis is that the adenosine-inosine axis acts as an immune-metabolic checkpoint that coordinates bioenergetic and receptor-signaling responses governing T-cell-mediated inflammation and autoimmunity. The approach integrates metabolome analysis, stable isotope tracing, transcriptome analysis, and T-cell function studies. Performance is in Columbus, Ohio 43205, with an ultimate completion date of August 31, 2031. The source identifies no sub-recipients for this award. The program supports biomedical research and research training in infectious diseases and related areas, including infectious, immunologic, and allergic diseases.
Description
- Abstract
- Properly allocating metabolic resources is crucial for supporting the energetically demanding processes of T- cell proliferation and inflammation that drive autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. Additionally, metabolites can act as ligands that interact with specific cell-surface receptors, shaping the T-cell response in physiological and pathological contexts. This proposal aims to understand how purine nucle- osides, specifically adenosine and inosine, regulate T-cell inflammation and explore the potential therapeutic benefits of targeting purine metabolism and signaling in animal models of autoimmune diseases. Through an integrated analysis of metabolome, stable isotope tracing, transcriptome, and T-cell function, we have revealed that effector T cells catabolize (i.e., break down to release energy) purine. We also discovered that purines engage cell surface purine-receptor signaling and intracellular purine catabolism differently, leading to opposing immune modulatory effects on T cells. Extracellular adenosine acts on the adenosine A2A receptor and SUP- presses T-cell inflammation. On the other hand, equilibrative and concentrative nucleoside transporters (ENTS/CNTS), along with adenosine deaminase (ADA), allow T cells to take up adenosine and convert IT into its immediate metabolic product, inosine. Subsequently, purine nucleoside phosphorylase (PNP) breaks down INO- sine, producing carbon and energy that support T-cell proliferation and inflammation. Accordingly, genetically or pharmacologically ablating purine catabolizing enzyme PNP in T cells suppresses inflammation and autoimmun- ITY in vivo. Hence, we hypothesize that the adenosine-inosine axis acts as an immune-metabolic checkpoint coordinating bioenergetic and receptor-signaling responses to regulate T-cell-mediated inflammation and autoimmunity. The aims of this proposal are to 1) decipher the molecular and signaling mechanisms that control purine metabolism in T cells; 2) determine the outcomes of modulating purine metabolism and receptor signaling in regulating the effector function of T cells; and 3) develop and test complementary pharmacological, genetic, and metabolic strategies to modulate inflammatory response and autoimmunity in animal models. This project's expected out- comes are significant as they will reveal the fundamental principles of the emerging connections between cell metabolism, signaling, and T-cell autoimmunity. Notably, the PNP inhibitor (FORODENSINE) and ADA inhibitor (PENTOSTATIN) were clinically used to treat leukemia. Our proposed preclinical studies are innovative as they will repurpose these two drugs for treating autoimmunity. These studies are critical to developing novel approaches and therapeutic interventions that improve clinical outcomes of autoimmune diseases such as multiple sclero- SIS and rheumatoid arthritis.
Quick answers
Who received award R37AI114581?
R37AI114581 was awarded to Research Institute At Nationwide Children's Hospital by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 31, 2026.
How much is award R37AI114581 worth?
$490,216 has been obligated on R37AI114581.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award